- Home
- TCBX vs AUTL Comparison
TCBX vs AUTL Comparison
Compare TCBX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBX | AUTL |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.8M | 433.8M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TCBX | AUTL |
|---|---|---|
| Price | $39.85 | $1.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $41.67 | $8.33 |
| AVG Volume (30 Days) | 63.3K | ★ 2.7M |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.90 | N/A |
| EPS | ★ 3.56 | N/A |
| Revenue | ★ $192,224,000.00 | $51,128,000.00 |
| Revenue This Year | $25.36 | $672.42 |
| Revenue Next Year | $22.36 | $84.48 |
| P/E Ratio | $10.74 | ★ N/A |
| Revenue Growth | 20.96 | ★ 406.67 |
| 52 Week Low | $25.17 | $1.11 |
| 52 Week High | $41.70 | $2.70 |
Technical Indicators
Market Signals| Indicator | TCBX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 42.47 |
| Support Level | $37.54 | $1.33 |
| Resistance Level | $39.27 | $1.97 |
| Average True Range (ATR) | 1.18 | 0.13 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 97.33 | 18.09 |
Price Performance
Historical ComparisonAbout TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.